A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy.

Trial Profile

A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Amlodipine/telmisartan (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2016 Status changed from recruiting to completed.
    • 17 Oct 2012 Planned number of patients changed from 900 to 600 as reported by ClinicalTrials.gov.
    • 11 Mar 2011 Planned End Date changed from 1 Dec 2013 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top